GSK2647544

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Alzheimer's Disease

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

CompletedNCT01702467

GlaxoSmithKlineAlzheimer's Disease

Start: 2012-10-19End: 2013-05-15Updated: 2017-10-18

GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers

TerminatedNCT01978327

GlaxoSmithKlineAlzheimer's Disease

Start: 2013-11-22End: 2014-03-03Updated: 2017-06-08

Related Papers

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects

Molecular Imaging and Biology2016-07-1117 citations